Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of LY2944876 in Healthy Volunteers
NCT02188303Phase 1Terminated
- Sponsor
- OPKO Health
- Start
- Jul 2014
- Primary completion
- Dec 2014
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pegapamodutide in type 2 diabetes mellitus (T2DM) (6 arms), sponsored by OPKO Health. Primary endpoint: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to Be Related to Study Drug Administration. Started Jul 2014; status: terminated.
02
Drugs
pegapamodutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02188303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02188303.